Besides that, some somatic mutations of the ErbB2 gene, termed activating mutations, increasing ErbB2 phosphotyrosine kinase activity or dimerization effectiveness are found in ErbB2+ breast cancer patients [9]. This evidence concerns the gene ERBB2 and breast cancer.